,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
[]
standing ovation for destiny-4! pfs 9.9mos, os 23.4mos in hr+/hr- disease. a phenomenal drug with a high potency payload, drug:antibody ratio + significant bystander effect. practice changing results! #asco22 
Physician | IM- @baystateIM l PGY-5 Hematology/Oncology- UT Houston l Chief Fellow 22-23| Interests: SCD, thoracic oncology, clinical education| Tweets are mine